CLYM Climb Bio, Inc.
Legal ·
Climb Bio filed a complaint in Delaware Superior Court against Alumis Inc. and Acelyrin, Inc. It asks for a declaration that budoprutug is not a Product under a 2024 asset purchase agreement, and that Climb does not owe a $3 million milestone payment.
Climb Bio agreed on December 11, 2025 to take back 20,440,000 shares from an entity affiliated with RA Capital in exchange for a pre-funded warrant. After the exchange, RA Capital and its affiliates will hold about 23.0% of the voting power, and the filing describes no cash payment to the company.
The sales agent earns up to 3.0% of gross sales. Climb Bio reported $212.5 million of cash and securities at year end and expects to fund operations through 2027.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $46.7 million | $14.3 million |
| Net income (loss) | -$59.9 million | -$73.9 million |
| Cash from operations | -$54.4 million | -$15.6 million |
| Cash and equivalents | $35.7 million | $87.2 million |
| Short-term investments | $65.4 million | $63.7 million |
Our latest story on this, dated Mar 25, 2025: "Climb Bio sets up $22,350,000 at-the-market stock program with Oppenheimer". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Dec 31, 2025: "Climb Bio sues Alumis and Acelyrin over $3 million budoprutug milestone payment". The story links the filing or release it is based on. Read the story.
Climb Bio, Inc. trades under the ticker CLYM on NASDAQ.
Climb Bio, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Climb Bio, Inc. is 1768446. Its filings are on SEC EDGAR.
57,436,255 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Climb Bio, Inc. under United States.
Our directory classifies Climb Bio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Climb Bio, Inc. is US28658R1068.
aibio.space lists Climb Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Climb Bio, Inc. reported a net loss of $59.9 million for the fiscal year ended Dec 31, 2025, and used $54.4 million of cash in operations, per its annual report to the SEC.
$46.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
$183.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Climb Bio, dated Dec 31, 2025: "Climb Bio sues Alumis and Acelyrin over $3 million budoprutug milestone payment". Climb Bio filed a complaint in Delaware Superior Court against Alumis Inc. and Acelyrin, Inc. It asks for a declaration that budoprutug is not a Product under a 2024 asset purchase agreement, and that Climb does not owe a $3 million milestone payment. Source.
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio